Qualigen Therapeutics (NASDAQ:QLGN – Get Free Report) is expected to post its results after the market closes on Tuesday, August 18th. Analysts expect the company to announce earnings of ($70.00) per share and revenue of $1.20 million for the quarter.
Qualigen Therapeutics Stock Down 0.4%
Shares of Qualigen Therapeutics stock opened at $0.82 on Tuesday. Qualigen Therapeutics has a 52 week low of $1.61 and a 52 week high of $8.81. The firm’s 50 day moving average is $1.06 and its two-hundred day moving average is $1.27. The firm has a market capitalization of $1.39 million, a P/E ratio of -0.11 and a beta of 0.24.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
See Also
- Five stocks we like better than Qualigen Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
